A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age

NCT00657683 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Invasive Group B Streptococcus (GBS) Disease

Interventions

BIOLOGICAL: Monovalent GBS-CRM glycoconjugate vaccine
BIOLOGICAL: Placebo

Sponsor

Novartis Vaccines